Actuate Therapeutics
ACTU1.1708.33% ( +0.090 )
Actuate Therapeutics (ACTU)
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead...
- Open
- 1.090
- High
- 1.190
- Low
- 1.060
- Prev. Close
- 1.080
- Volume
- 269.39K
- Turnover
- 311.82K
- Avg Price
- 1.158
- Bid/Ask Ratio
- --
- Amplitude
- 12.04%
- 52wk High
- 9.220
- Volume Ratio
- 1.98
- Turnover Ratio
- 3.14%
Actuate Therapeutics Analyst Rating
View MoreForecast & Rating
Jun 10, 2026Price forecast
$9.98752.78%
Forecast & RatingStrong buy
4analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · 9 hours ago
This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
- TradingView · Jul 17 at 03:33 PM
Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
- benzinga_article · Jul 14 at 12:05 PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
- rttnews · Jul 13 at 09:35 PM
Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus
- benzinga_article · Jul 13 at 12:05 PM
12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga_article · Jun 9 at 02:52 PM
Actuate Therapeutics shares are trading higher after the company announced that elraglusib will be evaluated in the BEACON2 clinical trial to identify and advance treatment approaches for children with relapsed and refractory neuroblastoma.
